The company's injectable platform is designed to regenerate and reconnect damaged lymphatic vessels, restoring natural lymphatic function without invasive surgery or lifelong compression therapy. Based in Houston, SteerBio is advancing its lead program toward the clinic to improve outcomes for millions of patients affected by lymphatic disease worldwide.